8-K: Myomo Announces $15 Million Public Offering to Fuel Growth and Product Development

Myomo, a wearable medical robotics company, has announced a public offering of common stock to raise approximately $15 million for growth initiatives and product development.

Summary

• Myomo, Inc. has entered into an underwriting agreement to sell 3,000,000 shares of its common stock at $5.00 per share.
• The underwriter, Craig-Hallum Capital Group LLC, has exercised its option to purchase an additional 450,000 shares.
• The offering is expected to close on December 6, 2024, subject to customary closing conditions.
• Myomo estimates net proceeds of approximately $15.8 million from the offering, after deducting underwriting discounts, commissions, and expenses.
• The company plans to use the proceeds to accelerate revenue growth by increasing advertising and headcount in its direct billing channel.
• Investments will also be made in systems to support growth in the orthotics and prosthetics (O&P) channel and to scale operations.
• A portion of the funds will be allocated to product development and sustaining engineering to enhance the MyoPro product line and develop next-generation products.
• The remaining funds will be used for working capital and general corporate purposes.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as the company is raising capital for growth and product development, but there are inherent risks associated with the offering and future execution.

Positives

• The capital raise will allow Myomo to accelerate its revenue growth by funding increased advertising and headcount.
• The company will invest in systems to support growth in the O&P channel, which should improve efficiency and reach.
• The funds will enable Myomo to enhance its current MyoPro product line and develop next-generation products, which could lead to future revenue streams.
• The offering provides additional working capital and general corporate funds, strengthening the company's financial position.

Negatives

• The offering will dilute existing shareholders' ownership.
• The company is reliant on the successful execution of its growth plans to justify the capital raise.
• The company is subject to market conditions and the offering may not close as expected.

Risks

• The company's ability to complete the offering on favorable terms is subject to general market conditions.
• There is a risk that the company may not be able to effectively use the proceeds to achieve its growth objectives.
• The company's future performance is subject to risks detailed in its filings with the SEC, including its annual and quarterly reports.
• The company's forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from expectations.

Future Outlook

Myomo expects to use the net proceeds to accelerate revenue growth, invest in systems, and fund product development, with the remainder for working capital and general corporate purposes. The company's future performance is subject to risks and uncertainties.

Management Comments

• Myomo expects to use the net proceeds from the Offering, together with its existing cash and cash equivalents, to accelerate its revenue growth by funding an increase in advertising expenses and headcount to support the expected revenue growth in the Companys direct billing channel, along with investments in systems to support growth in the orthotics and prosthetics (O&P) channel and in scaling the Companys operations.
• In addition, the Company expects the net proceeds will be used to fund product development and sustaining engineering activities to enhance the current MyoPro product line and to develop the next generation of the Companys products, with the remainder for working capital and general corporate purposes.

Industry Context

This offering reflects a trend in the medical device industry where companies seek capital to fund growth and innovation. Myomo's focus on wearable robotics for neurological disorders positions it in a growing market segment.

Comparison to Industry Standards

• The offering size of $15 million is relatively small compared to larger medical device companies, but is typical for a company of Myomo's size and stage.
• The use of proceeds for sales and marketing, product development, and working capital is a common strategy for companies in the growth phase.
• Comparable companies in the medical robotics space, such as ReWalk Robotics and Ekso Bionics, have also raised capital through public offerings to fund their operations and growth.
• The pricing of the offering at $5.00 per share will be evaluated by investors in the context of Myomo's current valuation and future growth potential.

Stakeholder Impact

• Shareholders will experience dilution due to the issuance of new shares.
• Employees may benefit from increased headcount and investment in the company.
• Customers may benefit from enhanced products and services.
• Suppliers may see increased business opportunities.
• Creditors may see an improvement in the company's financial position.

Next Steps

• The offering is expected to close on December 6, 2024, subject to customary closing conditions.
• Myomo will use the net proceeds to fund its growth initiatives and product development plans.
• The company will continue to file reports with the SEC as required.

Key Dates

Keywords

public offering, common stock, capital raise, medical robotics, MyoPro, revenue growth, product development, underwriting, Craig-Hallum Capital Group, orthotics, prosthetics